Navigation Links
Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients
Date:5/16/2008

1) receptor blockade -- in one molecule to treat high blood pressure.

"We are very pleased with the results of this important Phase 2a trial and look forward to future studies which will further assess the potential of PS433540, perhaps even beyond blood pressure lowering," said Joseph A. Mollica, Ph.D., Chairman of the Board and Interim President and Chief Executive Officer of Pharmacopeia. "We believe PS433540's dual mechanism of action may have a positive effect on diabetic kidney disease."

Patients with diabetes are at an increased risk for many complications, including high blood pressure and diabetic kidney disease. Up to 73 percent of patients with diabetes have been or are being treated for high blood pressure,(5) and an estimated 20-30 percent of diabetic patients will progress to diabetic kidney disease,(6) a devastating disease that may require patients to undergo dialysis or a kidney transplant.(7)

Pharmacopeia recently initiated a 12-week, Phase 2b clinical trial with PS433540 to evaluate the compound's safety and efficacy at three different doses versus placebo in 375 subjects with Stage I and Stage II hypertension. The study will also compare blood pressure reductions for each dose with irbesartan. Pharmacopeia anticipates completion of the Phase 2b trial at the end of 2008.

About the Phase 2a study

In this prospective study, 234 men and women with Stage I and Stage II hypertension entered into a single blind placebo run-in period for 3-4 weeks, after which 114 were randomized to receive double blind study medication for four weeks. At the time of the database lock, 108 subjects were available for evaluation, 93 of whom had both baseline and follow-up ambulatory blood pressure measurements (placebo: 25; PS433540 200mg: 35; PS433540 500mg: 33). The primary endpoint was the subjects' change from baseline in mean 24-hour systolic ambulatory blood pressure after 4 weeks of treatment. Additionally, investigators evaluated
'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Pharmacopeia Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540
2. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
3. Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
4. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
5. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
6. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
7. Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
8. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
9. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
10. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
11. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... -- Eli Lilly and Company (NYSE: LLY ) ... Conference on Tuesday, June 9, 2015. Jeffrey Simmons ... will participate in a fireside chat at 2:20 p.m., ... webcast will be available on the "Webcasts & Presentations" ... A replay of the fireside chat will be available ...
(Date:5/29/2015)... SAN DIEGO and BOSTON ... a leader in instrument development, custom automation, and contract ... developer of the Nanopatch™ needle-free drug delivery technology, have ... for development of the Nanopatch Jet Coating Instrument ... drug delivery research and product development.  The award was ...
(Date:5/29/2015)... SAN DIEGO , May 29, 2015 /PRNewswire/ ... single cell sequencing data, from metastatic castrate resistant ... of the American Society for Clinical Oncology. This ... no cell left behind™ platform to ... study revealed that late stage patients have heterogeneous ...
Breaking Medicine Technology:Lilly to Participate in Goldman Sachs Global Healthcare Conference 2Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 2Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 3Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 2Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 3
... Thomson CompuMark , the global leader in trademark ... Reuters, today announced the launch of Global Pharmaceutical ... intelligence in a single online report. Avoiding ... to prescription errors, is a critically important public health ...
... Span-America Medical Systems, Inc. (NASDAQ:  SPAN) will provide ... call on Friday, February 3, 2012, covering results for ... after the regular close of trading the preceding day. ... will be available online at www.spanamerica.com under ...
Cached Medicine Technology:Thomson CompuMark Reduces Drug Approval Delays by Identifying Conflicting Trademarks in International Markets 2Thomson CompuMark Reduces Drug Approval Delays by Identifying Conflicting Trademarks in International Markets 3
(Date:5/29/2015)... AB (PRWEB) May 29, 2015 External Counterpulsation, ... great heart disease treatment for patients. The Heart Fit Clinic ... and has released a raving review from patients who are ... Fit Clinic and underwent 35 treatments of ECP treatment and ... be seen here. Not only does the clinic perform this ...
(Date:5/29/2015)... 29, 2015 An organizational consultant and ... is losing his memory and may be suffering from ... both his professional life and in his uncertain relationship ... a hob-knobbing career working with corporate and government movers ... as multiple family members around him are being diagnosed ...
(Date:5/29/2015)... May 29, 2015 Testosterone Centers of Texas ... area, is opening a new center in the Mid-Cities area ... of the Mid Cities. Located on the south side of ... Hurst, the new testosterone center will open in May and ... suffer from low testosterone. , Like TCT’s other testosterone clinics, ...
(Date:5/29/2015)... 2015 The 3D Certificate program is ... the business, finance, and engineering aspects of evaluating 3D ... technology, an expansion in their existing 3D investment, or ... of 3D technology in manufacturing in various fields, will ... will include courses that cover the following topics: state ...
(Date:5/29/2015)... Thursday, May 21st was the inaugural Red ... walks of life came together to raise money for kids ... a campaign dedicated to raising money for children and young ... people laugh, the people at Hands-On Seminars decided to host ... they provided food, fun and laughter to their visitors, while ...
Breaking Medicine News(10 mins):Health News:External Counterpulsation at Heart Fit Clinic Receives Raving Review 2Health News:‘Forgetful’ Professor Struggles With Dementia in Compelling New Novel 2Health News:Testosterone Clinics in Colleyville — TCT opens Hurst Location 2Health News:Testosterone Clinics in Colleyville — TCT opens Hurst Location 3Health News:Second Cohort in 3D Certificate Program to Launch in August by Graduate School 2Health News:Second Cohort in 3D Certificate Program to Launch in August by Graduate School 3Health News:Groups, such as Hands-On Physical Therapy, Across the Country, Host Their Own Events and Make the Inaugural Red Nose Day a Huge Success 2
... Effect of mutation blunted in people with above-average activity scores, ... activity may reduce the risk of obesity in people with ... (BMI), says a U.S. study. , Recent research has ... mass and obesity associated with the (FTO) gene. The ...
... provoking manuscript addressing key challenges facing the industry. , ... ... -- From pioneering research and profound insight into the inner ... addressing key challenges facing the industry. The article is published ...
... Sept. 8 The nation faces,challenges in utilizing ... health, according to a NASA-sponsored report issued Monday,by ... report examines the computer-based decision support tools that ... in areas such as,agricultural productivity, air quality, renewable ...
... Celebrates its 50th anniversary this holiday season, ... nonprofit,Minneapolis-based Courage Center, announces its new 2008 Courage ... Courage Cards is,celebrating its 50th anniversary as a ... announce our 2008 Courage Cards artists:, Bonnie ...
... at Children,s Hospital of ... ... Worldwide, Inc. (NYSE: HOT ) newest lifestyle brand, which,opened in ... 2008 by welcoming home and congratulating Olympic,Gold Medalist Brendan Hansen., ...
... Samuels, CEO of The,Marketing Doctor LLC, is happy ... ... fertility specialist Dr. Peyman Saadat of Tyler,Medical ... well-respected fertility,specialist in the medical field and The ... In addition they have created strategic alliances,with celebrities, ...
Cached Medicine News:Health News:Vigorous Exercise Aids Those With Obesity-Related Gene 2Health News:New Paper Reveals Reasons for Payer Discontent with Disease Management 2Health News:Report Explores Use of Earth Data to Support National Priorities 2Health News:Report Explores Use of Earth Data to Support National Priorities 3Health News:Courage Cards Announces 2008 Fine Art Holiday Greeting Card Collection 2Health News:Courage Cards Announces 2008 Fine Art Holiday Greeting Card Collection 3Health News:Courage Cards Announces 2008 Fine Art Holiday Greeting Card Collection 4Health News:Courage Cards Announces 2008 Fine Art Holiday Greeting Card Collection 5Health News:Courage Cards Announces 2008 Fine Art Holiday Greeting Card Collection 6Health News:Courage Cards Announces 2008 Fine Art Holiday Greeting Card Collection 7Health News:Courage Cards Announces 2008 Fine Art Holiday Greeting Card Collection 8Health News:aloft(SM) hotels Congratulates Hometown Olympic Swimmer and Gold Medalist Brendan Hansen Friday, September 12, 2008 2